Meet Antisense Pharma at ASCO 2011
|| Print ||
|Thursday, 19 May 2011 11:00 (UTC + 2)|
Take the Opportunity of Background Discussions in Chicago, Illinois
Regensburg, Germany, May 19, 2011 / B3C newswire / - The German company Antisense Pharma is dedicated to the development of antisense-technology based anticancer drugs. Recently an international pivotal Phase III trial with its compound trabedersen has started in the US – and is enrolling brain tumor patients. The initiation of a Phase II/III study to confirm the encouraging safety and efficacy results in advanced pancreatic cancer patients begins in 2012.
Learn more about the remarkable mode of action of trabedersen and the important role of its target protein Transforming Growth Factor Beta 2 (TGF-β2) in several aggressive cancer diseases.
Get a better understanding of the TGF-β2 related research of Antisense Pharma – and answers to pertinent questions like
Do you have other questions concerning our company, ongoing or planned clinical trials, current preclinical and clinical data? Would you like to speak to one of the investigators who are already familiar with trabedersen? It’ll be a pleasure to arrange an exclusive interview at ASCO 2011, Chicago, 3rd – 6th June.
Take the opportunity and get in touch with us personally or attend our contribution to the oral presentation Developmental Therapeutics - Clinical Pharmacology and Immunotherapy, June 6, 3.15 – 3.30 pm.! We are looking forward to meeting you!
Antisense Pharma Abstract selected for oral presentation at ASCO 2011
ASCO 2011 Oral Abstract Session
At your request, we will arrange an exclusive talk with an interview partner of your choice, e.g. Karl-Hermann Schlingensiepen, MD PhD (CEO & Founder), Hubert Heinrichs, MD PhD MBA (CMO), Peter Kießling, PhD (Head Clinical Research) or a clinical investigator familiar with trabedersen in brain tumor or other cancer patients.
Please get in touch with Carolin Nolte / Antisense Pharma GmbH